Last reviewed · How we verify
NCT06019221: PRP
Pediatric Relapsing Polychondritis : Diagnosis and Management in a French Retrospective Study
trial in Relapsing Polychondritis in 20 participants. Status unknown.
18 January 2024
Quick facts
| Lead sponsor | University Hospital, Strasbourg, France |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 18 February 2023 |
| Primary completion | 18 January 2024 |
| Estimated completion | 18 January 2024 |
| Sites | 1 location across France |
Conditions studied
- Relapsing Polychondritis — all drugs for Relapsing Polychondritis →
Sponsor
University Hospital, Strasbourg, France
Who can join
Adults 1 to 17, any sex, with Relapsing Polychondritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The incidence in pediatrics is very low (about 3.5 per million per year according to a 2015 study) and therefore the data on the pathology very poor, especially on the therapeutic level. Without appropriate treatment, the disabling sequelae, even involving the vital prognosis, are significant. However, in paediatrics, therapeutic habits have been extrapolated from adult data and lack precision. Existing treatments are almost composed of immunomodulatory and/or immunosuppressive treatments. Different therapeutic lines have been introduced over the years and a better understanding of the pathology. More recently, biotherapies have been introduced in this pathology, but data on their effectiveness remain limited. Data on the evolution under therapy in children are thus still poor. Complications related to the pathology that can jeopardize the vital prognosis and the response to treatment for this pathology deserve to be studied in order to be known and if possible avoided. The aim of the study is to describe French practices and compare the lines of treatment proposed for juvenile atrophic polychondritis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06019221
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsing Polychondritis
Currently open trials in the same condition.
- NCT06873100 — Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis · Phase 1, PHASE2 · recruiting
- NCT02257866 — Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis · recruiting
Other University Hospital, Strasbourg, France trials
Trials by the same sponsor.
- NCT07418554 — Sleep Disturbances in Children and Adolescents With Post-traumatic Stress Disorder (PTSD): a Randomized Double-blind Pla · Phase 3 · not yet recruiting
- NCT07108582 — Reducing Chronic Pain After Lung Surgery: A Trial of Limiting NSAIDs During Recovery · Phase 3 · not yet recruiting
- NCT07302646 — Optimizing Reduced-Flow, Low-Volume Contrast Protocols for Cerebral Angiography in Unruptured Aneurysms · NA · not yet recruiting
- NCT07273968 — Clinical Study Evaluating the Effect of Virtual Reality on Reducing Patients' Anxiety During Wisdom Teeth Extraction · NA · not yet recruiting
- NCT07214103 — Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulop · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06019221 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Strasbourg, France
- Last refreshed: 2 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06019221.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing